CA3018635C - Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation - Google Patents

Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation Download PDF

Info

Publication number
CA3018635C
CA3018635C CA3018635A CA3018635A CA3018635C CA 3018635 C CA3018635 C CA 3018635C CA 3018635 A CA3018635 A CA 3018635A CA 3018635 A CA3018635 A CA 3018635A CA 3018635 C CA3018635 C CA 3018635C
Authority
CA
Canada
Prior art keywords
masitinib
pharmaceutically acceptable
acceptable salt
solvate
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3018635A
Other languages
English (en)
French (fr)
Other versions
CA3018635A1 (en
Inventor
Alain Moussy
Jean-Pierre Kinet
Colin Mansfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of CA3018635A1 publication Critical patent/CA3018635A1/en
Application granted granted Critical
Publication of CA3018635C publication Critical patent/CA3018635C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3018635A 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation Active CA3018635C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162490.3 2016-03-25
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (2)

Publication Number Publication Date
CA3018635A1 CA3018635A1 (en) 2017-09-28
CA3018635C true CA3018635C (en) 2023-09-26

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3018635A Active CA3018635C (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Country Status (20)

Country Link
US (1) US10092564B2 (OSRAM)
EP (1) EP3240538B1 (OSRAM)
JP (2) JP7250312B2 (OSRAM)
KR (1) KR102293847B1 (OSRAM)
CN (1) CN108883108B (OSRAM)
AU (1) AU2017236177B2 (OSRAM)
BR (1) BR112018069515A2 (OSRAM)
CA (1) CA3018635C (OSRAM)
DK (1) DK3240538T3 (OSRAM)
EA (1) EA038531B1 (OSRAM)
ES (1) ES2899929T3 (OSRAM)
HU (1) HUE057398T2 (OSRAM)
IL (1) IL261856B (OSRAM)
MX (1) MX390495B (OSRAM)
NZ (1) NZ745778A (OSRAM)
PL (1) PL3240538T3 (OSRAM)
PT (1) PT3240538T (OSRAM)
SG (1) SG11201808106YA (OSRAM)
SI (1) SI3240538T1 (OSRAM)
WO (1) WO2017162884A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2018045217A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3425390B1 (en) 2016-11-25 2020-12-23 Genuv Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
CN116139135A (zh) * 2017-03-28 2023-05-23 诺华股份有限公司 治疗多发性硬化的方法
JP6957650B2 (ja) * 2017-05-30 2021-11-02 デシフェラ・ファーマシューティカルズ，エルエルシー 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１−［４−ブロモ−５−［１−エチル−７−（メチルアミノ）−２−オキソ−１，２−ジヒドロ−１，６−ナフチリジン−３−イル］−２−フルオロフェニル］−３−フェニルウレアおよびアナログの使用
JP7463281B2 (ja) * 2018-03-05 2024-04-08 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
KR20250057151A (ko) * 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (OSRAM) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ATE375342T1 (de) 2002-08-02 2007-10-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
WO2013010015A2 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
US10238649B2 (en) * 2012-10-04 2019-03-26 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
EP3388436B1 (en) * 2013-03-15 2020-08-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
US20160263110A1 (en) 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
SI3240538T1 (sl) 2022-02-28
EP3240538A1 (en) 2017-11-08
EA038531B1 (ru) 2021-09-10
PL3240538T3 (pl) 2022-01-31
KR20180125966A (ko) 2018-11-26
JP2019515884A (ja) 2019-06-13
EP3240538B1 (en) 2021-09-29
MX2018011349A (es) 2019-02-07
WO2017162884A1 (en) 2017-09-28
PT3240538T (pt) 2021-12-07
BR112018069515A2 (pt) 2019-04-16
JP7250312B2 (ja) 2023-04-03
AU2017236177A1 (en) 2018-09-20
US10092564B2 (en) 2018-10-09
NZ745778A (en) 2022-07-01
US20180117037A1 (en) 2018-05-03
IL261856A (en) 2018-10-31
CN108883108A (zh) 2018-11-23
KR102293847B1 (ko) 2021-08-26
DK3240538T3 (da) 2021-12-06
AU2017236177B2 (en) 2022-03-31
CA3018635A1 (en) 2017-09-28
CN108883108B (zh) 2021-08-06
SG11201808106YA (en) 2018-10-30
ES2899929T3 (es) 2022-03-15
JP2022037132A (ja) 2022-03-08
IL261856B (en) 2022-04-01
HUE057398T2 (hu) 2022-05-28
MX390495B (es) 2025-03-20
EA201800499A1 (ru) 2019-03-29

Similar Documents

Publication Publication Date Title
CA3018635C (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
KR101571163B1 (ko) 멜라토닌 효능제 치료
ES2824552T3 (es) Método de tratamiento con tradipitant
US9078894B2 (en) Treatment of severe persistant asthma with masitinib
US20140147415A1 (en) Treatment of mastocytosis with masitinib
US20180311236A1 (en) Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
CN106714819A (zh) 治疗普拉德‑威利综合征的方法
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
US20230089715A1 (en) Masitinib for the treatment of a multiple sclerosis patient subpopulation
CN104220072B (zh) 利用氨基吡啶治疗中风相关的感觉运动损伤的方法
US20160263110A1 (en) Use of masitinib for treatment of amyotrophic lateral sclerosis
US20050176725A1 (en) Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
EP4262801A1 (en) Masitinib for the treatment of alzheimer's disease
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途
HK1261581A1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
WO2021110737A1 (en) Use of masitinib for the treatment of eosinophilic asthma
WO2016071511A1 (en) Treatment of mast cell activation syndrome (mcas) with masitinib
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
CA3000894A1 (en) Treatment of severe systemic mastocytosis with masitinib
LI Newsletter May 2018

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928